Hematopoietic Stem Cell TransplantationTransplantation, HomologousGraft vs Host DiseaseTransplantation ConditioningHematopoietic Stem CellsHematologic NeoplasmsStem Cell TransplantationTransplantation, AutologousGraft vs Leukemia EffectPeripheral Blood Stem Cell TransplantationTransplantation ChimeraTissue DonorsBone Marrow TransplantationMyeloablative AgonistsTreatment OutcomeBusulfanGraft vs Tumor EffectLeukemiaHistocompatibilityChimerismRecurrenceWhole-Body IrradiationRetrospective StudiesHistocompatibility TestingStem CellsAllograftsVidarabineGraft SurvivalHematologic DiseasesCord Blood Stem Cell TransplantationMyelodysplastic SyndromesLeukemia, Myeloid, AcuteSiblingsLymphocyte TransfusionHLA AntigensImmunosuppressive AgentsRemission InductionHepatic Veno-Occlusive DiseasePrecursor Cell Lymphoblastic Leukemia-LymphomaHematopoiesisSurvival RateCytomegalovirus InfectionsSurvival AnalysisT-LymphocytesTransplantation ImmunologyAcute DiseaseTime FactorsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemic InfiltrationCombined Modality TherapyDisease-Free SurvivalCystitisBone Marrow CellsAnemia, AplasticTransplantation, IsogeneicMinor Histocompatibility AntigensOpportunistic InfectionsLymphocyte DepletionMice, Inbred C57BLHematopoietic Stem Cell MobilizationMultiple MyelomaCell DifferentiationSevere Combined ImmunodeficiencyNeoplasm, ResidualFlow CytometryFollow-Up StudiesSalvage TherapyLymphoproliferative DisordersAntigens, CD34Antilymphocyte SerumCyclophosphamideCytomegalovirusBronchiolitis ObliteransLiver TransplantationBone MarrowRisk FactorsImmunocompromised HostBlood Group IncompatibilityPhotopheresisMycosesThymus GlandHematopoietic SystemPrognosisImmunosuppressionFatal OutcomeLeukemia, MyeloidHemangioblastsAntineoplastic Combined Chemotherapy ProtocolsSurvivorsPrimary MyelofibrosisMesenchymal Stem Cell TransplantationGanciclovirFetal BloodCell TransplantationUnrelated DonorsPhosphoramidesCell LineageCells, CulturedIsoantigensChronic Disease